Oregon Public Employees Retirement Fund Acquires Shares of 111,592 Exelixis, Inc. (EXEL)

Oregon Public Employees Retirement Fund acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 111,592 shares of the biotechnology company’s stock, valued at approximately $1,977,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in EXEL. Dimensional Fund Advisors LP lifted its stake in Exelixis by 13.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,038,173 shares of the biotechnology company’s stock valued at $22,996,000 after purchasing an additional 121,770 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Exelixis by 5.1% in the 1st quarter. Principal Financial Group Inc. now owns 91,006 shares of the biotechnology company’s stock valued at $2,016,000 after purchasing an additional 4,445 shares during the last quarter. Royal Bank of Canada lifted its stake in Exelixis by 38.7% in the 1st quarter. Royal Bank of Canada now owns 451,677 shares of the biotechnology company’s stock valued at $10,005,000 after purchasing an additional 126,068 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in Exelixis by 32.2% in the 2nd quarter. State of Alaska Department of Revenue now owns 35,650 shares of the biotechnology company’s stock valued at $767,000 after purchasing an additional 8,690 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its stake in Exelixis by 6.1% in the 2nd quarter. Handelsbanken Fonder AB now owns 328,000 shares of the biotechnology company’s stock valued at $7,059,000 after purchasing an additional 19,000 shares during the last quarter. Institutional investors own 80.87% of the company’s stock.

Shares of EXEL stock opened at $17.41 on Friday. The company has a market cap of $5.19 billion, a price-to-earnings ratio of 34.14 and a beta of 2.29. Exelixis, Inc. has a 12-month low of $13.42 and a 12-month high of $32.20.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Thursday, November 1st. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.22. The firm had revenue of $225.40 million during the quarter, compared to the consensus estimate of $174.14 million. Exelixis had a net margin of 49.53% and a return on equity of 63.91%. The business’s revenue for the quarter was up 47.8% compared to the same quarter last year. During the same period last year, the business posted $0.26 earnings per share. Sell-side analysts anticipate that Exelixis, Inc. will post 1.03 EPS for the current fiscal year.

In other Exelixis news, insider Patrick J. Haley sold 2,361 shares of the firm’s stock in a transaction that occurred on Monday, August 6th. The shares were sold at an average price of $20.92, for a total transaction of $49,392.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael Morrissey sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 7th. The stock was sold at an average price of $21.10, for a total transaction of $2,110,000.00. The disclosure for this sale can be found here. Insiders have sold 638,128 shares of company stock valued at $12,388,130 over the last 90 days. Company insiders own 4.80% of the company’s stock.

Several equities research analysts recently issued reports on the stock. Stifel Nicolaus cut their target price on shares of Exelixis from $29.00 to $25.00 and set a “hold” rating for the company in a research note on Wednesday, August 1st. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating and set a $25.00 target price for the company in a research note on Tuesday, July 31st. BidaskClub downgraded shares of Exelixis from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 11th. Morgan Stanley initiated coverage on shares of Exelixis in a research report on Monday, September 10th. They set an “underweight” rating and a $19.00 price objective for the company. Finally, Goldman Sachs Group initiated coverage on shares of Exelixis in a research report on Monday, September 17th. They set a “neutral” rating and a $22.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Exelixis currently has an average rating of “Buy” and a consensus price target of $29.78.

About Exelixis

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Story: Why Dividend Stocks May Be Right for You

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply